C0298067||Pirfenidone
C3665472||chemotherapy
C0556530||Normalization
C0932050||components
C0027651||tumor
C0015350||extracellular matrix
C0027651||tumor
C0005847||blood vessels
C0005847||vessel
C0087111||drug delivery
C0920425||cancer therapy
C0243095||tolerated
C1254351||pharmaceutical agents
C0280100||solid tumors
C3665472||chemotherapy
C2603343||study
C0298067||Pirfenidone
C0087111||treatment
C1800706||idiopathic pulmonary fibrosis
C0556530||normalization
C0574893||orthotopic
C0006141||mammary
C1710493||tumor models
C0298067||Pirfenidone
C0009325||collagen
C0813622||hyaluronan
C0005847||blood vessel
C0013089||doxorubicin
C0932050||extracellular matrix components
C0013081||downregulation
C1366557||TGFÎ²1
C1332772||COL1A1
C1413581||COL3A1
C1415475||HAS2
C1415476||HAS3
C0017262||expression
C0243095||findings
C0298067||Pirfenidone
C0035171||strategy
C0087111||drug delivery
C0280100||solid tumors
C0556530||normalizing